Loading...
A Price Too High: Cost, Supply, and Security Threats to Affordable Prescription Drugs
Senate Committee on Homeland Security and Governmental Affairs
Senate Committee on Homeland Security and Governmental Affairs
Abstract
The Senate Committee on Homeland Security and Governmental Affairs issued a Minority Staff Report on rising brand-name drug prices and the effects on U.S. public health and national security. The report contains recommendations.
Date
2019-12-06
Document Type
Senate Minority Staff Report
Serial Number
Document Length
60 pages
Congress
116
Files
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
321: Regulation of Drug Industry, Medical Devices, and Clinical Labs
Related Hearings
• House Committee on Energy and Commerce, Subcommittee on Consumer Protection and Commerce, hearing on "Profits over Consumers: Exposing How Pharmaceutical Companies Game the System," 116th Cong., H.Hrg. 116-63, (2019, September 19)
• House Committee on Ways and Means, Subcommittee on Health, hearing on "Promoting Competition to Lower Medicare Drug Prices," 116th Cong., (2019, March 7)
• House Committee on Oversight and Government Reform, Subcommittee on Healthcare, District of Columbia, Census and the National Archives, hearing on "Drug Shortage Crisis: Lives are in the Balance," 112th Cong., H.Hrg. 112-102, (2011, November 30)
• House Committee on Energy and Commerce, Subcommittee on Health, hearing on "Safeguarding Pharmaceutical Supply Chains in a Global Economy," 116th Cong., H.Hrg. 116-76, (2019, October 30)
• House Committee on Education and Labor, Subcommittee on Health, Employment, Labor, and Pensions, hearing on "Making Healthcare More Affordable: Lowering Drug Prices and Increasing Transparency," 116th Cong., H.Hrg. 116-42, (2019, September 26)
• House Committee on Energy and Commerce, Subcommittee on Health, hearing on "Examining FDA’s Generic Drug and Biosimilar User Fee Programs," 115th Cong., H.Hrg. 115-10, (2017, March 2)
• House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, hearing on "The Heparin Disaster: Chinese Counterfeits and American Failures," 110th Cong., H.Hrg. 110-109, (2008, April 29)
• Senate Committee on Armed Services, Subcommittee on Emerging Threats and Capabilities, hearing on "Biological Threats to United States National Security," 116th Cong., S.Hrg. 116-259, (2019, November 20)
• Senate Committee on Health, Education, Labor, and Pensions, hearing on "Continuing America’s Leadership in Medical Innovation for Patients," 114th Cong., S.Hrg. 114-572, (2015, March 10)
• House Committee on Oversight and Government Reform, Subcommittee on Healthcare, hearing on “The Causes of Drug Shortages and Proposals for Repairing these Markets,” 116th Cong., (2011, November 30)
• House Committee on Ways and Means, Subcommittee on Health, hearing on "Promoting Competition to Lower Medicare Drug Prices," 116th Cong., (2019, March 7)
• House Committee on Oversight and Government Reform, Subcommittee on Healthcare, District of Columbia, Census and the National Archives, hearing on "Drug Shortage Crisis: Lives are in the Balance," 112th Cong., H.Hrg. 112-102, (2011, November 30)
• House Committee on Energy and Commerce, Subcommittee on Health, hearing on "Safeguarding Pharmaceutical Supply Chains in a Global Economy," 116th Cong., H.Hrg. 116-76, (2019, October 30)
• House Committee on Education and Labor, Subcommittee on Health, Employment, Labor, and Pensions, hearing on "Making Healthcare More Affordable: Lowering Drug Prices and Increasing Transparency," 116th Cong., H.Hrg. 116-42, (2019, September 26)
• House Committee on Energy and Commerce, Subcommittee on Health, hearing on "Examining FDA’s Generic Drug and Biosimilar User Fee Programs," 115th Cong., H.Hrg. 115-10, (2017, March 2)
• House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, hearing on "The Heparin Disaster: Chinese Counterfeits and American Failures," 110th Cong., H.Hrg. 110-109, (2008, April 29)
• Senate Committee on Armed Services, Subcommittee on Emerging Threats and Capabilities, hearing on "Biological Threats to United States National Security," 116th Cong., S.Hrg. 116-259, (2019, November 20)
• Senate Committee on Health, Education, Labor, and Pensions, hearing on "Continuing America’s Leadership in Medical Innovation for Patients," 114th Cong., S.Hrg. 114-572, (2015, March 10)
• House Committee on Oversight and Government Reform, Subcommittee on Healthcare, hearing on “The Causes of Drug Shortages and Proposals for Repairing these Markets,” 116th Cong., (2011, November 30)